Penumbra’s THUNDERBOLT clearance strengthens Boston Scientific’s pending vascular device bet
Find out how Penumbra’s THUNDERBOLT FDA clearance could reshape stroke thrombectomy, CAVT adoption, and medtech competition.
Medical Devices & Diagnostics
Pharma & Biotech
Revalesio’s RNS60 program signals renewed momentum in adjunctive stroke therapeutics
Revalesio presents new RNS60 stroke data showing reduced brain tissue loss and shorter hospital stays. Discover what this could mean for stroke drug development.